Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
NCT04670978
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
96
Enrollment
OTHER
Sponsor class
Conditions
Objective Response Rate
Interventions
DRUG:
albumin-bound paclitaxe combined with bevacizumab biosimilar
Sponsor
Shandong University